Literature DB >> 12088728

Pharmacokinetics and brain distribution in non human primate of R(-)[123I]DOI, A 5HT(2A/2C) serotonin agonist.

Yolanda Zea-Ponce1, Lawrence S Kegeles, Ningning Guo, Leonid Raskin, Venkatesalu Bakthavachalam, Marc Laruelle.   

Abstract

Our goal was to synthesize with high specific activity R(-)-1-(2,5-Dimethoxy-4-[123I]iodophenyl)-2-aminopropane [R(-)[123I]DOI], an in vitro potent and selective 5-HT(2A/2C) serotonin agonist, and study in vivo its plasma pharmacokinetics and brain distribution in baboon by SPECT. The purpose was to evaluate this radiotracer as a potential tool in discerning the role of the agonist high affinity state of 5-HT(2) receptors in depression and other neurological disorders. The radiotracer was prepared by electrophilic radioiodination of the N-trifluoroacetyl precursor of R(-)-1-(2,5-Dimethoxyphenyl)-2-aminopropane [R(-)DMA-TFA] with high-purity sodium [123I]iodide in the presence of chloramine-T, followed by amino deprotection with KOH in isopropanol (labeling yield: 73%, radiochemical yield: 62%, radiochemical purity: 99%). In vivo studies in baboon showed high accumulation of radioactivity in thalamus, the frontoparietal cortex, temporal, occipital and the striatum regions, with slightly lower accumulation in the midbrain and cerebellum. Ketanserin did not displaced the radioactivity in any of these brain regions. Plasma metabolite analysis was performed using methanol protein precipitation, the methanol fractions contained from 68% to 92% of the mixture of a labeled metabolite and parent compound. The recovery coefficient of unmetabolized R(-)[123I]DOI was 68%. The percent parent compound present in the extracted fraction, measured by HPLC, decreased gradually with time from 99.8% to 0.3% still present after 4.7 hours post injection whereas the percentage of the only one detected metabolite increased conversely. Free fraction determination (f(1)), was 31 +/- 0.9% (n = 3). For comparison purposes, ex-vivo brain distribution, displacement and metabolite analysis was also carried out in rodents. Although R(-)[123I]DOI displayed good brain uptake and localized in serotonergic areas of the brain, its target to non target ratio and its insensitivity to ketanserin displacement suggest high nonspecific uptake, therefore non potentially useful as brain imaging radiotracer for visualization of the agonist high-affinity state of 5-HT(2A) receptors and for visualizing 5-HT(2C) receptors by SPECT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12088728     DOI: 10.1016/s0969-8051(02)00306-2

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  5 in total

1.  Effects of dopaminergic and serotonergic compounds in rats trained to discriminate a high and a low training dose of the synthetic cathinone mephedrone.

Authors:  Iman Saber; Andrew Milewski; Allen B Reitz; Scott M Rawls; Ellen A Walker
Journal:  Psychopharmacology (Berl)       Date:  2019-04-13       Impact factor: 4.530

Review 2.  Radiotracers for the Central Serotoninergic System.

Authors:  Reynald Mangeant; Emmanuelle Dubost; Thomas Cailly; Valérie Collot
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-03

3.  Sustained treatment with a 5-HT(2A) receptor agonist causes functional desensitization and reductions in agonist-labeled 5-HT(2A) receptors despite increases in receptor protein levels in rats.

Authors:  Ju Shi; Michelle Landry; Gonzalo A Carrasco; George Battaglia; Nancy A Muma
Journal:  Neuropharmacology       Date:  2008-06-07       Impact factor: 5.250

Review 4.  5-HT radioligands for human brain imaging with PET and SPECT.

Authors:  Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen
Journal:  Med Res Rev       Date:  2011-06-14       Impact factor: 12.944

Review 5.  Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.

Authors:  Paul Cumming; Milan Scheidegger; Dario Dornbierer; Mikael Palner; Boris B Quednow; Chantal Martin-Soelch
Journal:  Molecules       Date:  2021-04-22       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.